Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024839 | 0.81 | LMNA (0.44) | LMNATSHR | |
| SCHEMBL15907701 | 0.81 | TSHR (0.39) | LMNATSHRALDH1A1MAPK1ALOX15 | |
| SCHEMBL19180080 | 0.80 | LMNA (0.48) | LMNATSHR | |
| SCHEMBL19492877 | 0.78 | LMNA (0.52) | LMNATSHRALDH1A1 | |
| SCHEMBL28745209 | 0.78 | ALDH1A1 (0.35) | TSHRALDH1A1MAPK1ALOX15 | |
| SCHEMBL15065475 | 0.75 | TSHR (0.36) | TSHRALDH1A1MAPK1ALOX15 | |
| SCHEMBL17464898 | 0.73 | LMNA (0.41) | LMNATSHR | |
| SCHEMBL25234047 | 0.71 | LMNA (0.45) | LMNATSHR | |
| SCHEMBL4890864 | 0.71 | LMNA (0.40) | LMNAALDH1A1 | |
| SCHEMBL561352 | 0.70 | LMNA (0.54) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | LMNA 3635/4885TSHR 737/4885ALDH1A1 2515/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | LMNA 3635/4885TSHR 737/4885ALDH1A1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.